REMDACTA is expected to start enrolling patients in June, with researchers estimating they will recruit approximately 450 patients worldwide, including in the U.S., Canada, and Europe.
The post Phase III Trial to Study Combination of Genentech’s Actemra, Gilead’s Remdesivir vs. Severe COVID-19 appeared first on GEN - Genetic Engineering and Biotechnology News. […]
Although pregnancy has been linked to a reduced risk of developing breast cancer, a full understanding of the mechanisms involved is still in its infancy. Researchers from Cold Spring Harbor Laboratory (CSHL) report that pregnancy reprograms the epigenome in the mammary epithelial cells (MEC) of mice and influences the transcriptional output of the oncogenic transcription factor cMYC. The findings provide insight into the signals that may underpin the resistance to cancer formation.
The post Pregnancy May Reduce Cancer Risk through Epigenetic Reprogramming appeared first on GEN - Genetic Engineering and Biotechnology News. […]
James Wilson, a gene therapy pioneer, as well as AveXis, the gene therapy unit of the drug giant Novartis, have signed on to work on a new early stage vaccin […]